The Efficacy and Safety of Ramosetron in Patients Undergoing Off Pump Coronary Artery Bypass Surgery
Phase of Trial: Phase IV
Latest Information Update: 24 Nov 2015
Price : $35 *
At a glance
- Drugs Ramosetron (Primary)
- Indications Postoperative nausea and vomiting
- Focus Adverse reactions
- 19 Nov 2015 Status changed from recruiting to completed, as reported by ClinicalTrials.gov.
- 18 Nov 2014 Planned number of patients changed from 116 to 114 as per ClinicalTrials.gov record..
- 09 Jul 2014 New trial record